Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8116 to 8130 of 8896 results

  1. Lutonix drug-coated balloon for peripheral arterial disease (MIB72)

    NICE withdrew this medtech innovation briefing in October 2019 after the MHRA withdrew support for this type of technology being used in intermittent claudication for arterial disease.

    Withdrawn advice

  2. Ultroid 2.0 for internal haemorrhoids (MIB75)

    This medtech innovation briefing is temporarily unavailable, please contact mibs@nice.org.uk for further information.

    Withdrawn advice

  3. FebriDx for C-reactive protein and Myxovirus resistance protein A testing in primary care (MIB114)

    This advice has been updated and replaced by NICE medtech innovation briefing 224.

    Withdrawn advice

  4. VitalPAC for assessing vital signs of patients in hospital (MIB79)

    This advice has been updated and replaced by NICE medtech innovation briefing 205.

    Withdrawn advice

  5. UrgoStart for chronic wounds (MIB82)

    This advice has been updated and replaced by NICE medical technologies guidance 42.

    Withdrawn advice

  6. Absorb Bioresorbable Vascular Scaffold system for coronary artery disease (MIB84)

    NICE withdrew this medtech innovation briefing in November 2017 after the company stopped manufacturing Absorb because of low uptake. Some UK hospitals continue to use the technology in ongoing clinical studies.

    Withdrawn advice

  7. TheraSphere for treating operable and inoperable hepatocellular carcinoma (MIB62)

    This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.

    Withdrawn advice

  8. SIR-Spheres for treating inoperable hepatocellular carcinoma (MIB63)

    This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.

    Withdrawn advice

  9. Baloxavir marboxil for treating influenza in babies under 1 year [ID6555]

    Discontinued Reference number: GID-TA11712

    Technology appraisal guidance
    Discontinued

  10. Baloxavir marboxil for treating and preventing influenza in people 3 weeks to 11 years [ID6554]

    In development Reference number: GID-TA11732 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Intramedullary distraction for lower limb lengthening (IPG197)

    This guidance has been updated and replaced by NICE HealthTech guidance 613.

    Withdrawn guidance

  12. Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]

    In development Reference number: GID-TA11491 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]

    In development Reference number: GID-TA11511 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]

    In development Reference number: GID-TA11406 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Sipavibart for preventing COVID-19 [ID6282]

    In development Reference number: GID-TA11352 Expected publication date: TBC

    Technology appraisal guidance
    In development